Sparsentan is a drug used to treat primary immunoglobulin A nephropathy (IgAN) with a risk of rapid disease progression, improving the condition by lowering the patient's proteinuria levels. This article will provide a detailed description of its medication guidelines, the dosage of a course of treatment, and the precautions to be taken when taking the medication.
Guidelines for the use of Sparsentan
Knowing how to properly use Sparsentan is important for patients and healthcare providers to not only confirm efficacy, but also to avoid unwanted side effects.
Manufacturer and price
Sparsentan is developed and produced by Travere Therapeutic (TVTX) in the United States, with a specification of 400mg*30 tablets. In addition, it is produced by Lucius in Laos for the same specification, both of which are valid options.
Indications and Targets
Sparsentan is indicated in adults with IgAN, particularly those at risk for rapid disease progression and a urine protein-to-creatinine ratio (UPCR) of ≥ 1.5 g/g.
It mainly acts on ETAR and AT1R to help reduce proteinuria and protect kidney function.
By targeting specific targets, Sparsentan not only helps to control the progression of the disease, but also provides new therapeutic hope for patients.
The dosage of Sparsentan for one course of treatment
The correct dosage is the key to determining the effectiveness of the treatment, and adjusting the dosage according to the doctor's instructions can maximize the benefit of the drug.
Initial dose versus maintenance dose
The recommended initial dose is 200 mg once daily and can be increased to 400 mg once daily after 14 days if well tolerated. This step-by-step dose increase helps monitor the patient's response to the drug so that the best possible outcome can be achieved safely.
Missed doses and dose adjustments
If you miss a dose of medication, you should take the next dose at the normal time and never double the dose. When the dose needs to be adjusted, such as elevated aminotransferases or interactions with other drugs, it should be done under the guidance of a doctor.
Reasonable dose management can effectively prevent the occurrence of adverse reactions and clarify the treatment effect.
Precautions for the use of Sparsentan
While using Sparsentan, attention to potential risk factors and drug interactions is an important part of patient safety.
Hepatotoxicity and embryo-fetal toxicity
Because of the potential for severe hepatotoxicity and embryo-fetal toxicity, women should not begin treatment until they are confirmed to be pregnant, and use effective contraception throughout treatment. Regular monitoring of liver function and keeping an eye out for any unusual symptoms can help detect potential problems early.
Low blood pressure and other common side effects
Sepasentan may cause side effects such as hypotension and hyperkalemia, especially when used with other drugs. Keeping an eye on changes in your body and reporting any discomfort to your doctor in a timely manner is the basis for safe medication.
Having this critical information at your fingertips can help improve the safety and effectiveness of treatments, enabling patients to better cope with disease challenges.
